Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (481-490 of 636) with videos related to

Pageof 64
Sort By:
Journal of the American College of Cardiology|May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER TrialPascal Vranckx, Harvey D White, Zhen Huang, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
Journal of the American College of Cardiology|January 3, 2015
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)Karen A Hicks, James E Tcheng, Biykem Bozkurt, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 25, 2015
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)Karen A Hicks, James E Tcheng, Biykem Bozkurt, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Pageof 64

Showing results (481-490 of 636) with videos related to

Sort By:
Pageof 64
Journal of the American College of Cardiology|May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER TrialPascal Vranckx, Harvey D White, Zhen Huang, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Heart (British Cardiac Society)|June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillationMichael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
Journal of the American College of Cardiology|January 3, 2015
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)Karen A Hicks, James E Tcheng, Biykem Bozkurt, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
JACC. Cardiovascular Interventions|August 20, 2016
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF TrialMatthew W Sherwood, Derek D Cyr, W Schuyler Jones, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 25, 2015
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)Karen A Hicks, James E Tcheng, Biykem Bozkurt, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Pageof 64